Persistent Pulmonary Hypertension Of The Newborn — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for persistent pulmonary hypertension of the newborn. 66 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
66
Active US patents
67/100
Avg vulnerability
—
Annual revenue covered

Originators in Persistent Pulmonary Hypertension Of The Newborn

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Vero Biotech Inc 66 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating persistent pulmonary hypertension of the newborn. Each bar = one year. Y-axis scaled to peak year (28 patents).

2
26
1
27
28
29
2
30
26
31
3
35
3
36
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Inomax
NITRIC OXIDE
 Vero Biotech Inc 66 67 — 2026-10-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11931377 Inomax method of use 81 2029-06-30
11931377 Inomax method of use 81 2029-06-30
7947227 Inomax method of use 80 2026-10-17
8293284 Inomax method of use 73 2029-06-30
8846112 Inomax method of use 73 2029-06-30
8795741 Inomax method of use 73 2029-06-30
8431163 Inomax method of use 73 2029-06-30
8293284 Inomax method of use 73 2029-06-30
8431163 Inomax method of use 73 2029-06-30
8282966 Inomax method of use 73 2029-06-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10213572 Inomax formulation 42 2036-02-12
10737051 Inomax formulation 42 2035-10-20
8607785 Inomax formulation 48 2030-07-14
11103669 Inomax formulation 48 2030-06-21
8944049 Inomax formulation 48 2029-08-13
10926054 Inomax formulation 48 2029-08-13
8573209 Inomax formulation 53 2031-01-06
8573209 Inomax formulation 53 2031-01-06
9701538 Inomax formulation 55 2029-01-28
11511252 Inomax formulation 56 2029-09-21

Related